Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.09+0.01 (+0.06%)
Close on Nov 13, 2026Market cap $3.96BP/E –Yield –
Relay Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Relay Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -3094.6%. For fiscal 2025 it was -1971.6%, against -3722.1% the year before. The highest annual figure on record is -67.5% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1971.6% | +1750.5 |
| FY2024 | Dec 31, 2024 | -3722.1% | −2262.0 |
| FY2023 | Dec 31, 2023 | -1460.1% | +20210.8 |
| FY2022 | Dec 31, 2022 | -21670.9% | −9630.7 |
| FY2021 | Dec 31, 2021 | -12040.2% | −11972.7 |
| FY2020 | Dec 31, 2020 | -67.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -25949.7% | −24844.5 |
| Q1 FY2026 | Mar 31, 2026 | -2619.7% | −1716.7 |
| Q4 FY2025 | Dec 31, 2025 | -866.1% | −574.2 |
| Q2 FY2025 | Jun 30, 2025 | -11351.1% | +77766.5 |
| Q1 FY2025 | Mar 31, 2025 | -1105.2% | +43663.4 |
| Q1 FY2024 | Mar 31, 2024 | -903.0% | +27891.9 |
| Q3 FY2023 | Sep 30, 2023 | -291.9% | +24676.7 |
| Q2 FY2023 | Jun 30, 2023 | -89117.6% | −67799.6 |
| Q1 FY2023 | Mar 31, 2023 | -44768.6% | −29799.4 |
| Q4 FY2022 | Dec 31, 2022 | -28794.9% | −16850.8 |
| Q3 FY2022 | Sep 30, 2022 | -24968.6% | −15810.9 |
| Q2 FY2022 | Jun 30, 2022 | -21318.1% | +1617.9 |
| Q1 FY2022 | Mar 31, 2022 | -14969.2% | −10514.9 |
| Q4 FY2021 | Dec 31, 2021 | -11944.1% | – |
| Q3 FY2021 | Sep 30, 2021 | -9157.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -22936.0% | – |
| Q1 FY2021 | Mar 31, 2021 | -4454.3% | – |
See a number that looks wrong?